Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Monday 07 January, 2013


Sanofi Appoints Dr. Gary J. Nabel as Chairman o...

PR Newswire/Les Echos/


        Sanofi Appoints Dr. Gary J. Nabel as Chairman of the Strategic 
                  Development and Scientific Advisory Council

Paris, France - January 7, 2013 - Sanofi (EURONEXT : SAN ; NYSE : SNY) is
pleased to announce today the appointment of Dr. Gary J. Nabel, M.D., Ph.D., 
to Chairman of the Strategic Development and Scientific Advisory Council 

Dr. Nabel, currently Senior Vice President, Chief Scientific Officer and 
Deputy to Dr. Elias Zerhouni, President, Global R&D, will succeed Dr. Richard 
Klausner. As part of his key responsibilities as Chief Scientific Officer for 
global R&D, Dr. Nabel will direct the activities of the Council, including 
selection, appointment and evaluation of advisers.

"I am delighted that Dr. Gary Nabel will continue to make this Council a vital
part of our efforts to open Sanofi's research and development to outside
perspectives", said Dr. Elias Zerhouni, President, Global R&D, Sanofi. "I also
wish to recognize and warmly thank Dr. Richard Klausner who has been an
outstanding adviser to the Council. Under his leadership and invaluable
experience, he has played a key role in setting out the role and composition 
of a group of experienced and internationally recognized advisers."

Created in November 2010, the Council is a unique structure developed to 
enhance scientific discovery in a collaborative approach and to further 
develop a truly world-class research and development platform for future 
innovation for the benefit of patients around the world. The role of the 
Council is to advise Sanofi on new and emerging areas of science and 
technology as well as deepen Sanofi relationship with the external scientific 
world by creating a strong network of scientists and institutional 
partnerships. Dr. Richard Klausner occupied this position since March 1, 2011, 
providing overall direction and scientific leadership together with some of 
the most talented scientists around the world across the continuum from 
Discovery to Development to Delivery.

Dr. Gary J. Nabel Biography
Dr. Nabel has an extensive and distinguished background of academic and 
hospital appointments, and committee memberships including numerous 
prestigious awards and honors and an extensive publication record. He 
graduated magna cum laude from Harvard College in 1975 and continued his 
graduate studies at Harvard University, completing his Ph.D. in 1980 and his 
M.D. in 1982. He served as a postdoctoral fellow in the laboratory of David 
Baltimore at MIT's Whitehead Institute. Before his appointment at the Vaccine 
Research Center, Dr. Nabel served as the Henry Sewall Professor of Internal 
Medicine, Professor of Biochemistry, and Howard Hughes Medical Institute 
Investigator at the University of Michigan in Ann Arbor. In addition to his 
faculty positions, Dr. Nabel also served as the Director of the Center for 
Gene Therapy and co-director of the Center for Molecular Medicine at the 
University of Michigan. In recognition of his expertise at the forefront of 
virology, immunology, gene therapy, and molecular biology, Dr. Nabel was 
elected as a member of the Institute of Medicine of the National Academy of 
Sciences in 1998.

Dr. Richard Klausner Biography
Dr. Klausner is the former Executive Director for Global Health of the Bill 
and Melinda Gates Foundation. He was Director of the National Cancer Institute 
(NCI) between 1995 and 2001. He is currently partner at the Column Group, a 
San Francisco based venture firm. His research has been recognized with awards
including the Outstanding Investigator Award from the American Federation of
Clinical Research and the William Damashek Prize for major discoveries in
haematology. He received the 1997-1998 Dickson Prize in Medicine and the 1998
Raymond Bourgine Award. He has served as an Advisor to the Presidents of the
Academies on counterterrorism and as Liaison to the White House Office of
Science & Technology Policy. He is a member of the National Academy of 
Sciences, the Institute of Medicine and the American Academy of Arts and 
Sciences. Dr. Klausner is a past president of the American Society of Clinical 
Investigation and has been Chairman of the National Science Education 
Standards Projects of the National Academy of Sciences.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY).

Media Relations                 Investor Relations
Jean-Marc Podvin                Sébastien Martel
Tel.: + (33) 1 53 77 46 46      Tel.: + (33) 1 53 77 45 45
[email protected]                   [email protected]
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication.

a d v e r t i s e m e n t